BackChina Dasheng Biotechnology Company Overview
China Dasheng Biotechnology Company

China Dasheng Biotechnology Company Return on Equity

China Dasheng Biotechnology Company (CDBT) has a ROE of 3975.74%, above the sector sector average of 11.73%.

Get informed when a big investor buys or sells

+ Follow

ROE

3975.74%

Return on Equity

3975.74%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

China Dasheng Biotechnology Company (CDBT) FAQ

The latest ROE for CDBT is 3975.74%. That is above the sector sector average of 11.73%. Investors often review this figure alongside China Dasheng Biotechnology Company's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, CDBT currently prints 3975.74% for ROE, while the sector average sits near 11.73%. That is roughly 33782.7% above the sector mean. Large gaps often invite a closer look at China Dasheng Biotechnology Company's growth, margins, and balance sheet.

Return on Equity shows how effectively China Dasheng Biotechnology Company converts resources into returns. At 3975.74%, CDBT may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CDBT's ROE (3975.74%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.